Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 1/20 | 0.52 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.51 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.51 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.51 |
| ▸ | HTR6 | P50406 | 5/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | HTR1D | P28221 | 2/20 | 0.41 |
| ▸ | HTR2A | P28223 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8253461 | 0.85 | CHRNB2 (0.56) | TBXAS1CHRNB2CHRNA7CHRNA4HTR6 | |
| SCHEMBL13408067 | 0.81 | TBXAS1 (0.56) | TBXAS1CHRNB2CHRNA7CHRNA4HTR6 | |
| SCHEMBL9499656 | 0.80 | CHRNA7 (0.43) | TBXAS1CHRNB2CHRNA7CHRNA4HTR6 | |
| SCHEMBL16299526 | 0.78 | CYP19A1 (0.53) | CHRNB2CHRNA7CHRNA4HTR6MAPT | |
| SCHEMBL29415611 | 0.77 | ALDH1A1 (0.69) | HTR6MAPTMAPK1NPSR1ALDH1A1 | |
| SCHEMBL1424220 | 0.77 | ALDH1A1 (0.69) | HTR6MAPTMAPK1NPSR1ALDH1A1 | |
| SCHEMBL12425596 | 0.77 | TBXAS1 (0.56) | TBXAS1CHRNB2CHRNA7CHRNA4ALDH1A1 | |
| SCHEMBL11348399 | 0.77 | MAPT (0.65) | TBXAS1CHRNB2CHRNA7CHRNA4HTR6 | |
| SCHEMBL6216616 | 0.77 | CHRNB2 (0.55) | TBXAS1CHRNB2CHRNA7CHRNA4HTR6 | |
| SCHEMBL11965205 | 0.77 | TBXAS1 (0.52) | TBXAS1CHRNB2CHRNA7CHRNA4HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219888-A1 | PRENYLATED PSILOCYBIN DERIVATIVES AND METHODS OF USING | MAGICMED INDUSTRIES INC. (CA) | 2023-07-13 | — | — | US | disclosed |
| EP-1071664-A1 | SUBSTITUTED 2-OXO-ALKANOIC ACID- 2-(INDOL-3-YL)-ETHYL] AMIDES | BAYER AG (DE) | 2001-01-31 | — | — | EP | disclosed |
| WO-1999054301-A1 | SUBSTITUTED 2-OXO-ALKANOIC ACID-[2-(INDOL-3-YL)-ETHYL] AMIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1999-10-28 | — | — | WO | disclosed |
| EP-0201735-B1 | N-INDOLYLETHYL SULFON AMIDES, PROCESS FOR THEIR PREPARATION AND THEIR USE | BAYER AG (DE) | 1990-09-12 | — | — | EP | disclosed |
| US-4774240-A | ANTICOAGULANTS, ANTIALLERGENS, ANTIHISTAMINES | BAYER AKTIENGESELLSCHAFT (DE) | 1988-09-27 | — | — | US | disclosed |
| EP-0201735-A1 | N-indolylethyl sulfon amides, process for their preparation and their use | BAYER AG (DE) | 1986-11-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219888-A1 | PRENYLATED PSILOCYBIN DERIVATIVES AND METHODS OF USING | AANAT, ACAT2, PCYT1A | TBXAS1 469/4885CHRNB2 739/4885CHRNA7 1121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.